Search hospitals > Florida > Hollywood
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Claim this profileHollywood, Florida 33021
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Lymphoblastic Leukemia-Lymphoma
210 reported clinical trials
16 medical researchers
Summary
Memorial Regional Hospital/Joe DiMaggio Children's Hospital is a medical facility located in Hollywood, Florida. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Lymphoblastic Leukemia-Lymphoma and other specialties. Memorial Regional Hospital/Joe DiMaggio Children's Hospital is involved with conducting 210 clinical trials across 529 conditions. There are 16 research doctors associated with this hospital, such as Iftikhar Hanif, Luis E. Raez, Atif Hussein, and Delia C. Guaqueta.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Leukemia
Global LeaderStage II
Stage IV
Stage III
Top PIs
Iftikhar HanifMemorial Regional Hospital/Joe DiMaggio Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
44 reported clinical trials
99 drugs studied
Luis E. RaezMemorial Healthcare System6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Solid Tumors
10 reported clinical trials
18 drugs studied
Atif HusseinMemorial Healthcare System7 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
5 reported clinical trials
26 drugs studied
Delia C. GuaquetaMemorial Regional Hospital/Joe DiMaggio Children's Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
6 reported clinical trials
15 drugs studied
Clinical Trials running at Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Brain Tumor
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Leukemia
Astrocytoma
Osteosarcoma
Cancer
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Memorial Regional Hospital/Joe DiMaggio Children's Hospital?
Memorial Regional Hospital/Joe DiMaggio Children's Hospital is a medical facility located in Hollywood, Florida. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Lymphoblastic Leukemia-Lymphoma and other specialties. Memorial Regional Hospital/Joe DiMaggio Children's Hospital is involved with conducting 210 clinical trials across 529 conditions. There are 16 research doctors associated with this hospital, such as Iftikhar Hanif, Luis E. Raez, Atif Hussein, and Delia C. Guaqueta.